Clinical Trial Update: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial evaluating zotiraciclib for recurrent malignant gliomas with IDH1 or IDH2 mutations; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Zotiraciclib (zotiraciclib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Brain Tumor, Cancer | Phase 1, Phase 2 | Status: RECRUITING